| Name | Title | Contact Details |
|---|
BPR-Bechtel is a Sherbrooke, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Jeiven Pharmaceutical Consulting is a Scotch Plains, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Connecticut Orthopaedics is a premier team of orthopaedic doctors, surgeons and health care professionals that keep you moving forward with life. Learn more
Qosina is one of the leading medical device component suppliers of OEM components to medical and pharmaceutical industries. Explore our products today.
Trevi Therapeutics, Inc. is a late-stage clinical development company developing Nalbuphine® ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic, and neuropathic conditions. The Company is pursuing two conditions for clinical development: uremic pruritus and prurigo nodularis. Uremic pruritus is a persistent and debilitating itch in patients on dialysis that has been associated with significant impairment in quality of life and increased mortality. Prurigo nodularis is an intensely pruritic dermatologic condition characterized by unsightly and itchy skin papules and nodules. There are no approved therapies in the United States or Europe for either condition.